Aardvark Therapeutics ARD-101 Aardvarks lead candidate, oral ARD-101 , is a potent pan-agonist of bitter taste receptors (TAS2R) that stimulates enteroendocrine cells in the digestive tract, triggering the release of gut-peptide hormones like GLP-1 and cholecystokinin (CCK), a satiety hormone that activates gut-brain signaling to regulate hunger
Yes, but it is recommended to consult a healthcare professional before starting, especially if you are new to injectable supplements.
The findings paint a consistent picture of cellular remodeling in a protective direction
What payers require for Zepbound prior authorization Zepbound PA requirements are typically more stringent: Documented BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity Evidence of lifestyle intervention including documented participation in diet, exercise, and behavioral modification programs (usually for at least 3 to 6 months) Prior medication trials (some plans require documented failure of other weight management medications before approving tirzepatide) Specialist involvement (some plans require referral to or management by a bariatric medicine specialist, endocrinologist, or obesity medicine physician) Ongoing weight monitoring documentation with specific weight loss targets (typically 5% of baseline weight within 3 to 6 months of starting therapy) Patients researching BMI requirements for GLP-1 medications should understand that these thresholds directly correspond to the prior authorization criteria their provider must document
